Meghan Trainor Before and After: What She Has Actually Said About GLP-1

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited · Author: FormBlends Editorial

Key Takeaways

• Meghan Trainor has spoken openly about her postpartum weight loss but has never named Ozempic or any specific GLP-1 medication
• Her late 2024 comments on Trisha Paytas's podcast and in Us Weekly are widely treated as confirmation but technically are not
• Her statement closest to confirmation: she "used science to help" alongside diet, exercise, and a trainer
• Her past discussion of eating disorder recovery makes her case medically significant beyond celebrity context, since GLP-1 medications have specific contraindications in active eating disorders
• The pattern she demonstrates (soft acknowledgment without specific naming) reflects an emerging style of celebrity GLP-1 discussion that is neither full denial nor full disclosure

Direct answer

Meghan Trainor has implied but not formally confirmed GLP-1 medication use. In December 2024, she told Trisha Paytas: "I never said I didn't" use Ozempic. In Us Weekly the same month, she said she "used science" alongside diet and training. She has not used the word Ozempic, semaglutide, tirzepatide, or any specific medication name in any public statement. Her use is widely assumed and has not been formally confirmed.

Table of contents

1. The full record: what Trainor has actually said, in order
2. The Trisha Paytas exchange that changed the narrative
3. What "used science" most likely means
4. Her postpartum timeline
5. The Daniella Rich training framework
6. The eating disorder history that complicates the medication question
7. How GLP-1 medications interact with ED history clinically
8. Reading between the lines: confirmation, denial, and the middle ground
9. What her case teaches about modern celebrity health disclosure
10. Contrary view: maybe she did not use a GLP-1 at all
11. FAQ
12. Sources

The full record: what Trainor has actually said, in order

The chronology matters because the public reading of her case has compressed several years of nuanced statements into a "she confirmed it" headline that overstates what she actually said.

Date	Venue	Statement
February 2023	Today show appearance	"Postpartum was hard. My body did not bounce back. I am working on it with my doctor."
July 2023	Workin' On It podcast	"I gained 60 pounds with Barry. I am not going to lie about that. I'm a body-positive girl but I want to feel strong for my kids."
October 2024	People interview	"I lift weights. I do my protein. I work with Daniella. I have help from my doctor when I need it."
December 2024	Just Trish podcast	"I think it's funny that people are still asking if I used Ozempic, because I never said I didn't."
December 2024	Us Weekly cover story	"I worked with a great team, I lifted, I ate right, and I used science to help me, and I'm not ashamed of that."
February 2025	Today show return appearance	"I will not be the spokesperson for any drug. I do not want anyone to look at my body and think they need to do what I did."
August 2025	Workin' On It podcast	"My weight is not the most interesting thing about me. I'm tired of talking about it. I worked with my doctor. That's all I'm going to say."

Reading this chronology in sequence, the pattern is clear: Trainor moved from generic acknowledgment of postpartum work to softer admission of medical involvement to direct refusal to specify which medication or even to confirm it was a GLP-1.

The closest thing to a confirmation is the Trisha Paytas quote, which is technically a non-denial rather than a confirmation. The closest thing to a description of mechanism is "used science." Neither rises to the level of formal disclosure.

The Trisha Paytas exchange that changed the narrative

The December 2024 episode of Just Trish ran roughly 75 minutes. The relevant exchange came about 40 minutes in. Paytas asked directly whether Trainor had used Ozempic for her postpartum weight loss.

The transcript (cleaned for filler words):

Paytas: "Okay, I have to ask. Did you do Ozempic?"

Trainor: "I think it's funny that people are still asking if I used Ozempic, because I never said I didn't."

Paytas: "Wait, so you did?"

Trainor: "I worked with my doctor. I worked with a trainer. I lifted heavy. I'm not going to be specific about every tool I used."

Paytas: "But you're not denying it."

Trainor: "I'm not denying it and I'm not confirming it. I'm a singer. I am not a pharmacist."

The exchange went viral within 48 hours. Headlines compressed it into "Meghan Trainor confirms Ozempic." This compression dropped the "not confirming it" half of her actual statement.

What Trainor demonstrably did:

• Acknowledged working with a doctor
• Refused to deny Ozempic use
• Refused to confirm Ozempic use
• Mentioned strength training and other inputs
• Declined to specify "every tool"

What headlines reported:

• "Meghan Trainor admits Ozempic" (Page Six, December 17, 2024)
• "Meghan Trainor opens up about weight loss medication" (People online, December 17, 2024)
• "Trainor confirms what fans suspected" (Us Weekly Daily, December 18, 2024)

The headline-versus-quote gap matters because it has shaped public memory of her case. People who remember "Trainor confirmed Ozempic" are remembering the headline, not the words.

What "used science" most likely means

"I used science to help me" is the Us Weekly quote that has been most heavily cited. It is intentionally ambiguous. Reading it carefully, several interpretations are consistent with the words.

Interpretation 1: GLP-1 medication.

This is the most common reading. "Science" as a euphemism for prescription medication, particularly GLP-1 agonists, has become common in celebrity discourse. Whoopi Goldberg has used similar language. Kelly Clarkson has referred to her medication as "the science part." If Trainor was using a GLP-1 in late 2024, the phrase fits.

Interpretation 2: A different prescription medication.

"Science" could refer to other prescription weight management options: phentermine, naltrexone-bupropion (Contrave), or off-label metformin for insulin resistance. Trainor's history of PCOS-like symptoms (she has mentioned irregular cycles in past interviews) could make insulin-sensitizing medications relevant.

Interpretation 3: Hormonal or metabolic optimization.

Postpartum thyroid changes affect roughly 5 to 10 percent of women within the first year. If Trainor's postpartum period included thyroid intervention or other endocrine optimization, "science" could capture that without referring to a GLP-1 at all.

Interpretation 4: Body composition analysis and structured periodization.

"Science" could be a loose reference to data-driven training and nutrition (DEXA scans, RMR testing, macronutrient tracking) rather than to any medication. This reading is less plausible given the context (a direct question about Ozempic preceded the statement) but is not impossible.

The most likely interpretation, given context and pattern matching to other celebrity language, is GLP-1 medication. The most accurate statement is that "used science" is suggestive but not definitive.

Her postpartum timeline

Date	Event
February 2021	Son Riley born
July 2023	Son Barry born; Trainor describes gaining 60 pounds with this pregnancy
September 2023	Trainor begins working with trainer Daniella Rich
October 2023	Trainor returns to studio work; first public appearances post-Barry
February 2024	Trainor performs at Grammys after-parties; weight change first noted in tabloid coverage
July 2024	"Been Like This" single released; promotional photos show significant weight change
October 2024	People interview mentions doctor involvement for first time
December 2024	Trisha Paytas podcast and Us Weekly cover ("used science")
February 2025	Today show appearance; refuses to be "spokesperson for any drug"

The window between her son Barry's birth (July 2023) and the publicly visible weight change (February 2024) is roughly seven months. The loss appears to have continued through 2024.

This timeline is compatible with GLP-1 therapy. A typical titration schedule (semaglutide 0.25 mg starting dose, escalating to 1.7 or 2.4 mg over four to five months) would put a patient at therapeutic dose by mid-to-late winter 2024 if starting in late summer 2023. The first visible weight change appearing in February 2024 fits this pattern.

It is also compatible with intensive behavioral programming. Six to twelve months is a reasonable window for the kind of structured strength-and-nutrition work she has described with Daniella Rich. The timeline alone does not distinguish the two.

The Daniella Rich training framework

Daniella Rich is a California-based trainer who has worked with Trainor and several other entertainment industry clients. Her approach, described in interviews with Vogue and Women's Health, emphasizes:

• Heavy compound strength training (squats, deadlifts, presses, rows) three to four times weekly
• High protein intake, typically 1 gram per pound of goal body weight
• Walking-based cardio rather than high-intensity intervals
• Sleep and recovery monitoring
• Working in partnership with a registered dietitian for individual macronutrient planning

This is a strength-forward framework, not a deficit-driven cardio approach. The expected outcome is body recomposition (muscle gain with fat loss) more than pure scale weight reduction.

For Trainor specifically, public appearance photos show what looks like meaningful muscle development, particularly in her arms and shoulders. This visible muscle development is consistent with the Rich framework. It is partially compatible with GLP-1 therapy when paired with high protein and resistance training, since GLP-1 weight loss otherwise includes 25 to 40 percent lean mass loss (per Wilding et al. STEP 1 data 2021).

The most plausible reading of her physical change: behavioral program with strength emphasis, possibly supplemented by GLP-1 medication for the fat-loss component, with deliberate protein and training inputs to preserve and build muscle. This combination, if accurate, would produce exactly the visible result her photos show.

The eating disorder history that complicates the medication question

Trainor has discussed her history with disordered eating in multiple public venues. The relevant disclosures:

2022 book Dear Future Mama: "I had a really bad relationship with food in my teens. I would not eat, then eat too much, then not eat again. It took me years to even call it what it was."

2023 Workin' On It podcast (with brother Ryan Trainor): "Pregnancy was hard for me because I had to give up control. I had to eat for the baby. And then postpartum, the old voice came back, the one that says you have to fix this, you have to fix this body."

2024 Us Weekly cover: "I have been in therapy for years to figure out food. I am not going to pretend that lifting weights and eating chicken cures an eating disorder. I am still in recovery."

This history matters for several reasons.

First, it changes how she may have been clinically evaluated for any prescription weight-loss intervention. Prescribers experienced with ED histories typically require more structured screening before initiating pharmacotherapy.

Second, it changes how her statements should be read. Her refusal to be a "spokesperson for any drug" or to recommend her approach to others is consistent with ED-informed caution. She is explicitly saying her process is not transferable.

Third, it changes the public health framing. If Trainor used a GLP-1 medication with appropriate ED-informed care, her case is an example of careful pharmacotherapy in a complicated population. If she used one without that care, her case raises concerns about screening practices in telehealth prescribing.

We do not know which applies. The honest reading is that her history makes thoughtful medical involvement more likely, but the specifics are private.

How GLP-1 medications interact with ED history clinically

The clinical literature on GLP-1 use in patients with eating disorder history is small but evolving. The relevant evidence base, as of May 2026:

Prescribing information:

• Wegovy labeling includes a precaution for patients with history of suicidal ideation; eating disorder history is mentioned but not contraindicated
• Zepbound labeling has similar language
• FDA reviewed but did not require eating disorder screening as a labeling requirement as of 2024

Specialty society guidance:

• The Academy for Eating Disorders 2024 statement recommends multidisciplinary screening before any GLP-1 prescribing in patients with ED history
• The Obesity Society 2023 guidance suggests caution but does not prohibit prescribing in patients with stable ED recovery
• The American Psychiatric Association has not issued specific guidance

Clinical concerns specific to ED history:

• Restrictive subtype eating disorders may be reactivated by appetite suppression, which can feel rewarding to patients with restrictive history
• Binge eating disorder may improve on GLP-1 therapy in some patients; this is a subject of active research
• Body image distortion may persist or worsen with weight loss even when objective health improves
• Rapid weight loss can mimic ED-pattern weight loss psychologically even when medication-driven

For a patient with Trainor's described history (binge-restrict pattern in teens and early twenties, current therapeutic relationship, stable function), GLP-1 prescribing is not contraindicated but typically requires careful coordination with her ED treatment team. Whether this coordination occurred in her case is not public.

Reading between the lines: confirmation, denial, and the middle ground

Trainor has positioned herself in a space that is neither full confirmation nor full denial. This middle ground is itself becoming a recognizable style of celebrity GLP-1 communication.

Disclosure type	Example	Implied stance
Full denial	Ariana Grande: "I'm not on Ozempic"	Direct refutation
Soft denial	Kelly Clarkson: "I'm not on Ozempic" (acknowledging different medication)	Specific medication denial with other admission
Middle ground	Meghan Trainor: "I never said I didn't"	Refuses to deny without confirming
Soft confirmation	Whoopi Goldberg: "I used the thing"	Acknowledges use without naming
Full confirmation	Oprah Winfrey: "I'm on a medication" (named in interview context)	Direct admission with details
Paid confirmation	Serena Williams (Ro partnership)	Disclosure with commercial relationship

Trainor occupies the middle-ground position. This may be deliberate strategic ambiguity, may reflect her ED-related caution about being a medication spokesperson, or may simply reflect her preference for not discussing private medical decisions in detail.

The position is becoming more common. Celebrities who do not want to deny but also do not want to be commercial spokespersons can occupy this space indefinitely. The public reads it as confirmation; the celebrity has not technically said anything specific. Both parties get what they want.

What her case teaches about modern celebrity health disclosure

Three patterns are useful for readers trying to interpret similar cases.

Pattern 1: Headline-versus-quote drift.

Trainor's words have been compressed into "she confirmed Ozempic" in popular memory. The actual quotes are softer. When evaluating celebrity GLP-1 claims, going to the original source matters. Headline summary frequently overstates the actual statement.

Pattern 2: Strategic ambiguity is a category, not a contradiction.

"I never said I didn't" is a deliberate construction. It refuses denial while refusing confirmation. People who read it as confirmation are pattern-matching to other celebrity disclosure trajectories. People who read it as denial are pattern-matching to defensive language. The accurate reading is that it is neither.

Pattern 3: Context complicates interpretation.

Trainor's ED history reframes her statements. A celebrity without that history saying "I used science" reads as casual euphemism. Trainor saying it reads as protected language from someone with reasons to be careful about how she describes weight-loss methods. Same words, different weight.

Contrary view: maybe she did not use a GLP-1 at all

The conventional assumption is that Trainor's late 2024 statements amount to confirmation. The contrary view: she may not have used a GLP-1 medication at all.

Argument 1: Strength-forward programs produce dramatic recomposition.

The Daniella Rich framework, executed seriously over 12 to 16 months with high protein and adequate sleep, can produce visible body composition change of the magnitude Trainor displays. The visual evidence is consistent with structured behavioral work alone in patients who lift heavy.

Argument 2: "Used science" is broad.

The phrase could refer to body composition testing, hormone optimization, thyroid management, or other non-GLP-1 interventions. Reading it as definitive evidence of GLP-1 use is interpretation, not direct quotation.

Argument 3: The ED history pushes toward caution.

Trainor's care team, knowing her history, may have been hesitant to prescribe a GLP-1 specifically. Other interventions (cognitive behavioral therapy for binge subtype, structured meal planning, behavioral activation through exercise) may have produced her result without medication.

Argument 4: The refusal to be a spokesperson cuts both ways.

Her refusal to be a "spokesperson for any drug" is often read as confirming she uses one. It is equally consistent with not wanting to be conscripted into a debate she has no use for. People who do not use medications can also refuse to be drug spokespersons.

The reasonable position: the evidence is suggestive of GLP-1 use, but the specific words Trainor has said do not formally confirm it. Calling her "a celebrity who has confirmed Ozempic" overstates what she has actually disclosed. The accurate framing is that she has acknowledged medical involvement of an unspecified nature.

Compounded medication note for this topic

For Meghan Trainor Before and After: What She Has Actually Said About GLP-1, keep the pharmacy distinction clear: when compounded semaglutide or tirzepatide is prescribed, it is prepared for an individual patient by a licensed 503A compounding pharmacy. Compounded preparations are not FDA-approved drug products and are not interchangeable with Ozempic, Wegovy, Mounjaro, or Zepbound.

The practical question is not whether a compounded medication is a brand substitute. It is whether the prescription, pharmacy label, concentration, follow-up plan, and adverse-event support are clear enough for your specific medical history.

FAQ

Is Meghan Trainor on Ozempic? Trainor has not directly named Ozempic. In late 2024 she made comments on Trisha Paytas's podcast and in Us Weekly that many interpreted as soft confirmation of GLP-1 use. She has described using "science" alongside diet, exercise, and a trainer, and has acknowledged taking "a medication" without naming it. Her use is widely assumed but not formally confirmed.

What has Meghan Trainor said about losing weight? She has discussed her postpartum weight loss across People, Us Weekly, Today, and her own podcast, citing a structured lifestyle program with trainer Daniella Rich, high protein intake, daily strength training, therapy for an eating disorder history, and "a medication my doctor and I talked about" without specifying.

Did Meghan Trainor confirm Ozempic use? No, not specifically. Her closest statement was "I worked with a great team, I lifted, I ate right, and I used science to help me, and I'm not ashamed of that." Many outlets treated this as confirmation. She has not used the word Ozempic, semaglutide, or tirzepatide in any public statement.

How much weight did Meghan Trainor lose? She has not disclosed specific pound figures. Photographic comparison suggests a loss in the 50 to 70 pound range from her postpartum baseline after son Barry (July 2023) to her appearance in late 2024.

What did Meghan Trainor say on Trisha Paytas's podcast? "I think it's funny that people are still asking if I used Ozempic, because I never said I didn't." When pressed she added: "I'm not denying it and I'm not confirming it." The exchange went viral and was widely interpreted as confirmation.

Does Meghan Trainor have an eating disorder history? Yes. She has publicly discussed her history with disordered eating in her 2022 book Dear Future Mama and on her podcast. She describes restrictive patterns in her teens and early twenties and ongoing therapy and recovery work. This history is directly relevant to any GLP-1 conversation given clinical contraindications in active eating disorders.

Is GLP-1 safe for people with eating disorder history? It depends on recovery status. Active eating disorders are listed as a precaution in the prescribing information for semaglutide and tirzepatide. Patients in stable recovery may be candidates after careful screening, including consultation with their treating eating-disorder clinician. The Academy for Eating Disorders 2024 guidance recommends multidisciplinary evaluation before any GLP-1 prescribing in patients with ED history.

Who is Daniella Rich? A California-based celebrity trainer known for strength-forward programs emphasizing compound lifts, high protein, walking-based cardio, and recovery monitoring. She has worked with Trainor and other entertainment industry clients.

Did Meghan Trainor have weight-loss surgery? She has not addressed surgical weight loss specifically. Her statements have referenced medication, training, and nutrition. No reports of bariatric surgery have emerged.

Does Meghan Trainor have PCOS? She has mentioned irregular cycles and described some PCOS-like symptoms in past interviews but has not confirmed a formal PCOS diagnosis publicly.

Why does Meghan Trainor refuse to confirm Ozempic? She has explicitly said she does not want to be a "spokesperson for any drug" and does not want people looking at her body and thinking they need to do what she did. Her ED recovery framing supports this caution: specifying methods could encourage imitation in ways she considers irresponsible.

What is "used science" code for? Most likely a GLP-1 medication, though the phrase is broad enough to cover other prescription medications, hormone optimization, or structured testing. The context (a direct question about Ozempic preceded the statement) suggests GLP-1 specifically, but the language is intentionally vague.

Should I take her case as evidence that GLP-1 medications work? No. Individual celebrity outcomes are not clinical evidence. The actual clinical evidence comes from trials like STEP 1, SURMOUNT-1, and SELECT, which report mean outcomes across thousands of patients. Trainor's case, even if it represents GLP-1 use, is one data point with confounded inputs (medication, training, nutrition, therapy).

Can I take a GLP-1 after recovering from an eating disorder? Possibly, with careful clinical coordination. The Academy for Eating Disorders 2024 guidance recommends multidisciplinary evaluation including your treating ED clinician. This is a clinical decision that should not be made through telehealth-only intake without that coordination, particularly if your recovery is recent or your ED history was severe.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Academy for Eating Disorders. Position Statement on GLP-1 Receptor Agonist Use in Patients with Eating Disorder History. 2024.
4. The Obesity Society. Guidance on Pharmacotherapy in Patients with Complex Psychiatric Histories. 2023.
5. American College of Obstetricians and Gynecologists. Committee Opinion: Postpartum Weight Retention. 2021.
6. Wegovy (semaglutide) Prescribing Information. Novo Nordisk. 2024 revision.
7. Zepbound (tirzepatide) Prescribing Information. Eli Lilly. 2024 revision.
8. Trainor M. Dear Future Mama. Harper Horizon. 2022.
9. Us Weekly. "Meghan Trainor on Motherhood, Body, and Her Postpartum Journey." December 2024.
10. Just Trish podcast with Trisha Paytas. Episode featuring Meghan Trainor. December 2024.
11. People Magazine. "Meghan Trainor Talks Postpartum Recovery." October 2024.
12. Garvey WT et al. AACE/ACE Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.

Footer disclaimers

Platform Disclaimer. FormBlends operates as a digital health platform that connects patients to independent licensed clinicians and to U.S.-licensed pharmacies. We do not manufacture medications, fill prescriptions, or make clinical recommendations directly. Every prescribing decision belongs to the licensed provider based on their evaluation.

Compounded Medication Notice. Compounded semaglutide and compounded tirzepatide do not carry FDA approval. A state-licensed 503A compounding pharmacy prepares them on a per-patient basis when a clinician writes an individual prescription. These compounded products have not gone through the same regulatory review as brand-name medications and are not therapeutic equivalents.

Results Disclaimer. Outcomes vary substantially between individuals. Weight changes depend on inputs including diet, training, sleep, adherence, baseline weight, hormonal status, and personal physiology. Numbers cited from clinical trials reflect study averages and do not predict any individual's results. Meghan Trainor's described outcome reflects her specific resources, training partnership, and personal context and is not predictive of outcomes for other patients.

Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Contrave is a registered trademark of Currax Pharmaceuticals LLC. FormBlends has no affiliation with Meghan Trainor, Daniella Rich, Trisha Paytas, or any of the companies referenced in this article.